Breast cancer — neoantigen vaccine coverage

Clinical

Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk - News-Medical

Researchers evaluated an individualized neoantigen mRNA vaccine in early-stage TNBC, a subtype with high recurrence risk and no standard targeted therapies. The study demonstrates the feasibility, safety, and immunogenicity of the approach, noting lasting T cell immunity in patients. These findings offer early clinical signals that tailored vaccination may improve long-term outcomes, though larger trials are needed to confirm efficacy.

news · brief 2026-06-27 · published 2026-02-19

Clinical

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Washington University School of Medicine is preparing a Phase 1 trial to evaluate a personalized cancer immunotherapeutic (PCI) strategy with or without CD8-selective IL-2 mutein in triple negative breast cancer. The study aims to assess safety, feasibility, and immunogenicity during neoadjuvant chemoimmunotherapy.

clinicaltrials · brief 2026-06-16 · published 2026-05-07

Clinical

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

NEC Bio B.V. is conducting a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine's combination with standard-of-care chemotherapy and anti-PD-1 therapy, with potential post-surgical extension to assess immune response and clinical outcomes in early-stage disease.

clinicaltrials · brief 2026-06-08 · published 2026-05-26

Clinical

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

H. Lee Moffitt Cancer Center is recruiting for an early-phase 1 pilot protocol evaluating a personalized dendritic cell vaccine for high-risk triple-negative breast cancer. The vaccine utilizes whole exome sequencing data from residual tumors following neoadjuvant chemotherapy to assess safety, feasibility, and immunogenicity.

clinicaltrials · brief 2026-06-08 · published 2026-04-01

Clinical

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center is recruiting for a phase 1 trial of a personalized neo-antigen peptide vaccine combined with the Th1 polarizing adjuvant poly ICLC. The study targets stage IIIC-IV melanoma, metastatic breast cancer, and stage III-IV NSCLC to induce polyclonal cytolytic T cell immunity.

clinicaltrials · brief 2026-06-08 · published 2026-03-12

Clinical

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

The National Cancer Institute is conducting a phase 2 trial testing the addition of a personalized synthetic long peptide neoantigen vaccine to durvalumab, tremelimumab, and chemotherapy in metastatic triple-negative breast cancer. The study compares outcomes with and without the vaccine to determine if it enhances the efficacy of the existing regimen.

clinicaltrials · brief 2026-06-08 · published 2026-05-13

Clinical

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Washington University School of Medicine is launching a Phase I trial for triple-negative breast cancer, evaluating a personalized cancer immunotherapeutic (PCI) strategy with or without a CD8-selective IL-2 mutein fusion protein. The addition of IL-2 modulation aims to enhance CD8+ T cell expansion and persistence during neoadjuvant chemoimmunotherapy.

clinicaltrials · brief 2026-06-04 · published 2026-05-07

Clinical

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center has launched a Phase I trial recruiting patients with stage IIIC-IV melanoma, metastatic breast cancer, or stage III-IV NSCLC. The study evaluates a personalized neo-antigen peptide vaccine combined with the Th1-polarizing adjuvant poly ICLC to induce polyclonal cytolytic T cell immunity.

clinicaltrials · brief 2026-06-02 · published 2026-03-12

Clinical

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

The National Cancer Institute (NCI) is conducting a Phase II trial testing the addition of a personalized synthetic long peptide neoantigen vaccine to durvalumab, tremelimumab, and nab-paclitaxel in metastatic triple-negative breast cancer. This aims to determine if adding the vaccine improves outcomes over the standard chemo-immunotherapy backbone.

clinicaltrials · brief 2026-06-02 · published 2026-05-13

Clinical

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

H. Lee Moffitt Cancer Center and Research Institute is recruiting for a Phase I pilot evaluating a personalized dendritic cell vaccine for high-risk triple-negative breast cancer (TNBC). The study utilizes whole exome sequencing of residual tumors post-neoadjuvant chemotherapy to assess safety, feasibility, and immunogenicity.

clinicaltrials · brief 2026-05-30 · published 2026-04-01

Clinical

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

NEC Bio B.V. is recruiting for a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine, in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine in combination with standard-of-care anti-PD-1 therapy and chemotherapy, with potential post-surgical extension.

clinicaltrials · brief 2026-05-29 · published 2026-05-26